Exosome / regenerative injection therapy
An emerging regenerative-medicine technique using cell-derived exosomes, not currently offered pending confirmation of its legal and regulatory status in India.
What it is & how it works
Uses cell-derived exosomes — small extracellular vesicles thought to carry signalling molecules that may support tissue repair — injected into target tissue. This is an emerging area of regenerative medicine still under active research, with mechanism and clinical benefit not yet as well established as for autologous techniques such as PRP.
How it's done
Not currently a confirmed Unfold Longevity offering. If and when offered, general clinical practice elsewhere typically involves injection of a laboratory-processed exosome preparation into the target site under physician supervision; specific sourcing, processing, dosing, and session structure would need to be defined and confirmed against applicable regulation before any protocol is published.
Conditions it treats
Why Unfold Longevity
Unfold Longevity's evidence-bounded commitment means this therapy is not presented as an offered service, and will not be promoted, until its legal and regulatory status in India (including sourcing and biologics regulation) is confirmed — reflecting our stated position that we do not promote services before they are properly launched and approved.
Evidence & safety
Not to be presented as an offered service until its legal and regulatory status in India is confirmed. Would be considered, subject to confirmation, for select regenerative contexts overlapping with Sports Injury and, provisionally, Rejuvenation.
Related questions
No. Exosome therapy is not currently a confirmed Unfold Longevity offering — its legal and regulatory status in India, including sourcing and biologics regulation, has not yet been confirmed, and it is not promoted or provided until that review is complete.
In general clinical and research use, exosome therapy refers to injecting laboratory-processed, cell-derived exosomes — small vesicles thought to carry signalling molecules that may support tissue repair — into a target site. No exosome product currently holds FDA approval for any medical use in the United States, and regulatory bodies elsewhere similarly treat it as an investigational biologic still under active study, distinct from more established autologous techniques such as PRP.